FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794383404> ?p ?o ?g. }

• W2794383404 endingPage "285" @default.
• W2794383404 startingPage "278" @default.
• W2794383404 abstract "•A risk score that predicts HCC during antiviral therapy in patients with chronic hepatitis B is developed and validated. •The CAMD (cirrhosis, age, male sex, and diabetes mellitus) score requires only simple easily available information. •Patients with a CAMD score <8 and >13 points were exposed to distinctly lower and higher risks, respectively. Background & Aims The risk of hepatocellular carcinoma (HCC) during antiviral therapy in patients with chronic hepatitis B (CHB) is inadequately predicted by the scores built from untreated patients. We aimed at developing and validating a risk score to predict HCC in patients with CHB on entecavir or tenofovir treatment. Methods This study analysed population-wide data from the healthcare databases in Taiwan and Hong Kong to identify patients with CHB continuously receiving entecavir or tenofovir. The development cohort included 23,851 patients from Taiwan; 596 (2.50%) of them developed HCC with a three-year cumulative incidence of 3.56% (95% CI 3.26–3.86%). The multivariable Cox proportional hazards model found that cirrhosis, age (cirrhosis and age interacted with each other), male sex, and diabetes mellitus were the risk determinants. These variables were weighted to develop the cirrhosis, age, male sex, and diabetes mellitus (CAMD) score ranging from 0 to 19 points. The score was externally validated in 19,321 patients from Hong Kong. Results The c indices for HCC in the development cohort were 0.83 (95% CI 0.81–0.84), 0.82 (95% CI 0.81–0.84), and 0.82 (95% CI 0.80–0.83) at the first, second, and third years of therapy, respectively. In the validation cohort, the c indices were 0.74 (95% CI 0.71–0.77), 0.75 (95% CI 0.73–0.78), and 0.75 (95% CI 0.72–0.77) during the first three years, and 0.76 (95% CI 0.74–0.78) and 0.76 (95% CI 0.74–0.77) in the extrapolated fourth and fifth years, respectively. The predicted and observed probabilities of HCC were calibrated in both cohorts. A score <8 and >13 points identified patients at distinctly low and high risks. Conclusions The easily calculable CAMD score can predict HCC and may inform surveillance policy in patients with CHB during oral antiviral therapy. Lay summary This study analyses population-wide data from the healthcare systems in Taiwan and Hong Kong to develop and validate a risk score that predicts hepatocellular carcinoma during oral antiviral therapy in patients with chronic hepatitis B. The easily calculable CAMD score requires only simple information (i.e. cirrhosis, age, male sex, and diabetes mellitus) at the baseline of treatment initiation. With a scoring range from 0 to 19 points, the CAMD score discriminates the risk of hepatocellular carcinoma with a concordance rate of around 75–80% during the first three years on therapy. The risk prediction can be extrapolated to five years on treatment with similar accuracy. Patients with a score <8 and >13 points were exposed to distinctly lower and higher risks, respectively. The risk of hepatocellular carcinoma (HCC) during antiviral therapy in patients with chronic hepatitis B (CHB) is inadequately predicted by the scores built from untreated patients. We aimed at developing and validating a risk score to predict HCC in patients with CHB on entecavir or tenofovir treatment. This study analysed population-wide data from the healthcare databases in Taiwan and Hong Kong to identify patients with CHB continuously receiving entecavir or tenofovir. The development cohort included 23,851 patients from Taiwan; 596 (2.50%) of them developed HCC with a three-year cumulative incidence of 3.56% (95% CI 3.26–3.86%). The multivariable Cox proportional hazards model found that cirrhosis, age (cirrhosis and age interacted with each other), male sex, and diabetes mellitus were the risk determinants. These variables were weighted to develop the cirrhosis, age, male sex, and diabetes mellitus (CAMD) score ranging from 0 to 19 points. The score was externally validated in 19,321 patients from Hong Kong. The c indices for HCC in the development cohort were 0.83 (95% CI 0.81–0.84), 0.82 (95% CI 0.81–0.84), and 0.82 (95% CI 0.80–0.83) at the first, second, and third years of therapy, respectively. In the validation cohort, the c indices were 0.74 (95% CI 0.71–0.77), 0.75 (95% CI 0.73–0.78), and 0.75 (95% CI 0.72–0.77) during the first three years, and 0.76 (95% CI 0.74–0.78) and 0.76 (95% CI 0.74–0.77) in the extrapolated fourth and fifth years, respectively. The predicted and observed probabilities of HCC were calibrated in both cohorts. A score <8 and >13 points identified patients at distinctly low and high risks. The easily calculable CAMD score can predict HCC and may inform surveillance policy in patients with CHB during oral antiviral therapy." @default.
• W2794383404 created "2018-03-29" @default.
• W2794383404 creator A5002888892 @default.
• W2794383404 creator A5003037377 @default.
• W2794383404 creator A5005752443 @default.
• W2794383404 creator A5011571171 @default.
• W2794383404 creator A5014703182 @default.
• W2794383404 creator A5024370956 @default.
• W2794383404 creator A5027343826 @default.
• W2794383404 creator A5029738510 @default.
• W2794383404 creator A5029783320 @default.
• W2794383404 creator A5048137173 @default.
• W2794383404 creator A5087432386 @default.
• W2794383404 date "2018-08-01" @default.
• W2794383404 modified "2023-10-18" @default.
• W2794383404 title "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" @default.
• W2794383404 cites W1481091893 @default.
• W2794383404 cites W1923206005 @default.
• W2794383404 cites W1964491003 @default.
• W2794383404 cites W1966268267 @default.
• W2794383404 cites W1972833227 @default.
• W2794383404 cites W1972926465 @default.
• W2794383404 cites W1985860298 @default.
• W2794383404 cites W2000307707 @default.
• W2794383404 cites W2002144368 @default.
• W2794383404 cites W2009474584 @default.
• W2794383404 cites W2012824806 @default.
• W2794383404 cites W2016925307 @default.
• W2794383404 cites W2029455217 @default.
• W2794383404 cites W2039541436 @default.
• W2794383404 cites W2059560167 @default.
• W2794383404 cites W2063027176 @default.
• W2794383404 cites W2064387090 @default.
• W2794383404 cites W2078197314 @default.
• W2794383404 cites W2090379722 @default.
• W2794383404 cites W2090738619 @default.
• W2794383404 cites W2093208686 @default.
• W2794383404 cites W2104389844 @default.
• W2794383404 cites W2108147025 @default.
• W2794383404 cites W2109202667 @default.
• W2794383404 cites W2116836111 @default.
• W2794383404 cites W2120229610 @default.
• W2794383404 cites W2123664981 @default.
• W2794383404 cites W2131760769 @default.
• W2794383404 cites W2135847752 @default.
• W2794383404 cites W2138029572 @default.
• W2794383404 cites W2144790451 @default.
• W2794383404 cites W2155893993 @default.
• W2794383404 cites W2160533181 @default.
• W2794383404 cites W2162566260 @default.
• W2794383404 cites W2165984116 @default.
• W2794383404 cites W2262473304 @default.
• W2794383404 cites W2297828361 @default.
• W2794383404 cites W2311291553 @default.
• W2794383404 cites W2314866596 @default.
• W2794383404 cites W2331778563 @default.
• W2794383404 cites W2468199489 @default.
• W2794383404 cites W2511852572 @default.
• W2794383404 cites W2544387958 @default.
• W2794383404 cites W2548902797 @default.
• W2794383404 cites W2606125816 @default.
• W2794383404 cites W2616659724 @default.
• W2794383404 cites W2626176186 @default.
• W2794383404 cites W2757485239 @default.
• W2794383404 doi "https://doi.org/10.1016/j.jhep.2018.02.032" @default.
• W2794383404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29551708" @default.
• W2794383404 hasPublicationYear "2018" @default.
• W2794383404 type Work @default.
• W2794383404 sameAs 2794383404 @default.
• W2794383404 citedByCount "116" @default.
• W2794383404 countsByYear W27943834042018 @default.
• W2794383404 countsByYear W27943834042019 @default.
• W2794383404 countsByYear W27943834042020 @default.
• W2794383404 countsByYear W27943834042021 @default.
• W2794383404 countsByYear W27943834042022 @default.
• W2794383404 countsByYear W27943834042023 @default.
• W2794383404 crossrefType "journal-article" @default.
• W2794383404 hasAuthorship W2794383404A5002888892 @default.
• W2794383404 hasAuthorship W2794383404A5003037377 @default.
• W2794383404 hasAuthorship W2794383404A5005752443 @default.
• W2794383404 hasAuthorship W2794383404A5011571171 @default.
• W2794383404 hasAuthorship W2794383404A5014703182 @default.
• W2794383404 hasAuthorship W2794383404A5024370956 @default.
• W2794383404 hasAuthorship W2794383404A5027343826 @default.
• W2794383404 hasAuthorship W2794383404A5029738510 @default.
• W2794383404 hasAuthorship W2794383404A5029783320 @default.
• W2794383404 hasAuthorship W2794383404A5048137173 @default.
• W2794383404 hasAuthorship W2794383404A5087432386 @default.
• W2794383404 hasConcept C11783203 @default.
• W2794383404 hasConcept C120665830 @default.
• W2794383404 hasConcept C121332964 @default.
• W2794383404 hasConcept C126322002 @default.
• W2794383404 hasConcept C134018914 @default.
• W2794383404 hasConcept C203014093 @default.
• W2794383404 hasConcept C2522874641 @default.
• W2794383404 hasConcept C2776175608 @default.
• W2794383404 hasConcept C2777214474 @default.
• W2794383404 hasConcept C2777869810 @default.

• next